AOD-9604 (human growth hormone fragment 177–191) is a short peptide investigated for its effects on fat metabolism. In preclinical and early clinical research, it has shown lipolytic and anti‑lipogenic activity without elevating IGF‑1 or impairing glucose tolerance. This page provides an educational dosing and reconstitution framework commonly used for daily subcutaneous administration.

• Typical educational starting dose: 200–300 mcg once daily; gradual titration to 400–500 mcg as tolerated

• Reconstitution: Add 3.0 mL bacteriostatic water to the 2 mg vial (≈0.667 mg/mL)

• Reconstitution: Add 3.0 mL bacteriostatic water to the 5 mg vial (≈1.67 mg/mL solution)

• Syringe math (100‑unit insulin syringe): 10 units ≈ 0.10 mL ≈ 66.7 mcg for 2mg vial

• Syringe math (100‑unit insulin syringe): 10 units ≈ 0.10 mL ≈ 1.67 mg for 5mg vial

• Storage: Keep lyophilized vials frozen (≈ −20 °C); refrigerate reconstituted solution (2–8 °C), protected from light

• Frequency: Once daily subcutaneous injection (e.g., morning); maintain consistent timing